Why is gabapentin used in interstitial lung disease (ILD) for chronic cough control?

Gabapentin for ILD-Associated Refractory Chronic Cough

Gabapentin is used in interstitial lung disease (ILD) specifically for refractory chronic cough that persists despite treating underlying causes and comorbidities, based on the principle that these patients have cough hypersensitivity syndrome—a neuropathic condition requiring neuromodulation rather than traditional antitussives.

The Core Rationale

The 2018 CHEST guidelines explicitly recommend gabapentin for ILD patients with refractory chronic cough, treating it as unexplained chronic cough with underlying neural hypersensitivity 1. This approach recognizes that:

• Chronic cough in ILD severely impairs quality of life and often doesn't respond to conventional therapies 1
• The mechanism is neuropathic: ILD patients show increased cough reflex sensitivity to capsaicin and substance P, with elevated nerve growth factor in airways 1
• Gabapentin acts as a neuromodulator to dampen this hypersensitive cough reflex 2, 3

When to Use Gabapentin: The Clinical Algorithm

Step 1: Rule Out Treatable Causes First

Before considering gabapentin, you must systematically exclude:

• ILD disease progression (temporal association between worsening disease and cough onset)
• Drug side effects from immunosuppressive therapy
• Pulmonary infections
• GERD (77% of ILD patients with frequent cough have GERD symptoms) 1
• Asthma or eosinophilic bronchitis
• Upper airway cough syndrome

1

Step 2: Identify Refractory Cough

The cough is considered refractory when:

• Duration ≥8 weeks
• Significantly impairs quality of life
• Persists after addressing all identifiable causes above
• Patient exhibits features of cough hypersensitivity (triggered by low-level stimuli like talking, laughing, temperature changes)

1, 2

Step 3: Initiate Gabapentin

Dosing: Titrate to maximum tolerable dose up to 1800 mg/day in divided doses 2

Expected outcomes:

• Improved cough-specific quality of life (Leicester Cough Questionnaire scores improve by ~1.8 points)
• Reduced cough frequency
• Greatest benefit in patients with laryngeal hypersensitivity features

2, 4

Evidence Quality and Strength

The recommendation is based on:

• High-quality RCT evidence showing gabapentin significantly improves cough-specific quality of life compared to placebo (number needed to treat = 3.58) 2
• Consensus-based guideline statement from CHEST (2018), acknowledging limited direct evidence in ILD but strong rationale from unexplained chronic cough literature 1
• The guideline explicitly states this approach is reasonable given the "paucity of antitussive treatment options for refractory cough in ILD" 1

Critical Safety Considerations

Common Side Effects

• Somnolence and dizziness (19% vs 9% placebo for somnolence; 17% vs 7% for dizziness) 5
• Nausea and fatigue (31% in treatment group) 2
• Driving impairment—patients must not drive until they assess their tolerance 5

Serious Warnings in ILD Patients

This is crucial: Recent evidence shows gabapentin may increase risk of COPD exacerbations (HR 1.39) 6 and severe exacerbations requiring hospitalization (HR 1.35-1.58) 7, 6. While these studies focused on COPD, the respiratory risk is relevant for ILD patients.

The FDA warns of severe breathing problems with gabapentinoids, particularly in patients with respiratory risk factors 5.

Risk Mitigation Strategy

• Use gabapentin only when cough severely impairs quality of life and alternative treatments have failed
• Start low, titrate slowly
• Monitor closely for respiratory deterioration
• Consider this a quality-of-life intervention rather than disease-modifying therapy
• If gabapentin fails or is not tolerated, consider low-dose opiates in palliative care settings with monthly reassessment 1

The Treatment Hierarchy

1. First-line: Treat underlying ILD and comorbidities (especially GERD)
2. Second-line: Multimodality speech pathology therapy (cough suppression techniques, vocal hygiene) 1
3. Third-line: Gabapentin for refractory cases
4. Fourth-line: Low-dose opiates (5 mg slow-release morphine twice daily) in palliative care settings when all else fails 1

Common Pitfalls to Avoid

• Don't use gabapentin as first-line therapy—you'll miss treatable causes like GERD
• Don't prescribe PPIs empirically for IPF patients without documented GERD 1
• Don't use inhaled corticosteroids for sarcoidosis-associated cough (Grade 2C recommendation against) 1
• Don't ignore the respiratory safety signals—gabapentin may worsen respiratory function in vulnerable patients 7, 6
• Don't continue indefinitely without reassessing benefit—if no improvement in quality of life, discontinue

The evidence supporting gabapentin in ILD-specific cough remains limited, with ongoing trials 8, but the mechanistic rationale is strong and the guideline consensus supports its use when patients have exhausted other options and face severe quality-of-life impairment.